



VERITY Updates

- **VERITY announces the 2023 VERITY Pilot & Feasibility Research Awardee, Dr. Medha Barbhैया! Congratulations Dr. Barbhैया!**
- **VERITY is planning a VERITY Course alumni event at the 2023 ACR Annual Meeting in San Diego. More information to come!**

VERITY (NIH-P30-AR072577) is funded by NIH-NIAMS.

2023 VERITY Pilot & Feasibility Research Award

VERITY is pleased to announce the recipient of the 2023 P&F Award, Medha Barbhैया, MD, MPH! In May 2018, VERITY established the VERITY Pilot & Feasibility (P&F) Research Award, a NIAMS-supported, \$20,000 grant aimed at providing seed funding for new projects as well as to offer an opportunity to the VERITY Research Community to develop skills in proposal preparation.

Medha Barbhैया, MD MPH is an Assistant Attending Physician at Hospital for Special Surgery (HSS) and an Assistant Professor of Medicine and Population Health Sciences at Weill Cornell Medicine. Her research focuses on studying environmental and lifestyle risk factors and outcomes related to rheumatic diseases such as antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). She has previously received two three-year Rheumatology Research Foundation (RRF) Awards to study environmental risk factors in SLE as well as to support her role in helping to develop new APS classification criteria and studying APS risk factors. She has also been the recipient of various institutional grants at both BWH and HSS.



Her proposed project will develop and test algorithms for APS in collaboration with the BWH VERITY Bioinformatics Core. This work has great potential to provide the opportunity to study the longitudinal course of APS in large administrative datasets and multi-center electronic health record cohorts. Medha received the VERITY Pilot & Feasibility Award for this promising project and VERITY looks forward to working with Medha and her team.

VERITY Publications

Zaccardelli A, Wallace ZS, Sparks JA. Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic. *Curr Opin Rheumatol*. 2023 May 1;35(3):175-184.

Gan Z, Zhou D, Rush E, Panickan VA, Ho YL, Ostrouchov G, Xu Z, Shen S, Xiong X, Greco KF, Hong C, Bonzel CL, Wen J, Costa L, Cai T, Begoli E, Xia Z, Gaziano JM, Liao KP, Cho K, Cai T, Lu J. ARCH: Large-scale Knowledge Graph via Aggregated Narrative Codified Health Records Analysis. *medRxiv [Preprint]*. 2023 May 21:2023.05.14.23289955.

Hou J, Zhao R, Gronsbell J, Lin Y, Bonzel CL, Zeng Q, Zhang S, Beaulieu-Jones BK, Weber GM, Jemielita T, Wan SS, Hong C, Cai T, Wen J, Ayakulangara Panickan V, Liaw KL, Liao K, Cai T. Generate Analysis-Ready Data for Real-world Evidence: Tutorial for Harnessing Electronic Health Records With Advanced Informatic Technologies. *J Med Internet Res*. 2023 May 25;25:e45662.

Choi MY, Malspeis S, Sparks JA, Cui J, Yoshida K, Costenbader KH. Association of Sleep Deprivation and the Risk of Developing Systemic Lupus Erythematosus Among Women. *Arthritis Care Res (Hoboken)*. 2023 Jun;75(6):1206-1212.

2023 VERITY Course Alumni Event

VERITY plans to host a VERITY Course alumni event at this year's ACR Annual Meeting in San Diego. Keep an eye out for more details from VERITY!

Li L, Chang Y, Losina E, Costenbader KH, Chen AF, Laidlaw TM. Association of Reported Nonsteroidal Anti-Inflammatory Drug (NSAID) Adverse Drug Reactions With Opioid Prescribing After Total Joint Arthroplasty. *J Allergy Clin Immunol Pract*. 2023 Jun;11(6):1891-1898.e3.

Collins JE, Yang YH, Opare-Addo MB, Losina E. Quantifying sustained pain worsening in knee osteoarthritis. *Osteoarthritis Cartilage*. 2023 Jun;31(6):802-808.

Fa'ak F, Buni M, Falohun A, Lu H, Song J, Johnson DH, Zobniw CM, Trinh VA, Awiwi MO, Tahon NH, Elsayes KM, Ludford K, Montazari EJ, Chernis J, Dimitrova M, Sandigursky S, Sparks JA, Abu-Shawer O, Rahma O, Thanarajasingam U, Zeman AM, Talukder R, Singh N, Chung SH, Grivas P, Daher M, Abudayyeh A, Osman I, Weber J, Tayar JH, Suarez-Almazor ME, Abdel-Wahab N, Diab A. Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. *J Immunother Cancer*. 2023 Jun;11(6):e006814.

Das P, Weisenfeld D, Dahal K, De D, Feathers V, Coblyn JS, Weinblatt ME, Shadick NA, Cai T, Liao KP. Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis. *Arthritis Res Ther*. 2023 Jun 2;25(1):93.

Wallace ZS, Sparks JA, Robinson PC, Machado PM, Yazdany J. Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks *et al*. *Ann Rheum Dis*. 2023 Jul;82(7):e158.

Barbhैया M, Hart JE, Malspeis S, Tedeschi SK, VoPham T, Sparks JA, Karlson EW, Laden F, Costenbader KH. Association of Ultraviolet B Radiation and Risk of Systemic Lupus Erythematosus Among Women in the Nurses' Health Studies. *Arthritis Care Res (Hoboken)*. 2023 Jul;75(7):1409-1415.

Bass AR, Abdel-Wahab N, Reid PD, Sparks JA, Calabrese C, Jannat-Khah DP, Ghosh N, Rajesh D, Aude CA, Gedmintas L, MacFarlane L, Arabelovic S, Falohun A, Mushtaq K, Haj FA, Diab A, Shah AA, Bingham CO, Chan KK, Cappelli LC. Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. *Ann Rheum Dis*. 2023 Jul;82(7):920-926.

Wang F, Palmer N, Fox K, Liao KP, Yu KH, Kou SC. Large-scale real-world data analyses of cancer risks among patients with rheumatoid arthritis. *Int J Cancer*. 2023 Sep 15;153(6):1139-1150.

